Author: | Galsky, M. D. |
Article Title: | The role of taxanes in the management of bladder cancer |
Abstract: | Transitional cell carcinoma of the bladder is a chemosensitive neoplasm. Whereas the MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) regimen was long considered the standard of care for patients with advanced disease, the evaluation of newer agents with retained activity and improved tolerability has been the focus of much investigation over the past decade. Among the most important of these newer agents are taxanes. Whereas taxane-containing regimens have not yet been shown to improve the survival of patients with transitional cell carcinoma in randomized trials, ongoing phase III trials will further define the role of these agents in both the perioperative and advanced disease settings. ©AlphaMed Press. |
Keywords: | cancer survival; clinical trial; drug tolerability; fatigue; neutropenia; review; cisplatin; doxorubicin; area under the curve; side effect; gemcitabine; paclitaxel; chemotherapy; methotrexate; neurotoxicity; anorexia; carboplatin; infection; lung toxicity; nephrotoxicity; bone marrow suppression; mucosa inflammation; neuropathy; thrombocytopenia; antineoplastic combined chemotherapy protocols; bladder cancer; urinary bladder neoplasms; ifosfamide; vinblastine; docetaxel; asthenia; febrile neutropenia; confidence interval; death; adjuvant chemotherapy; cystectomy; taxoids; perioperative period; taxane derivative; carcinoma, transitional cell; deoxycytidine; transitional cell carcinoma; hematologic disease; fluid retention; clinical trials, phase ii |
Journal Title: | The Oncologist |
Volume: | 10 |
Issue: | 10 |
ISSN: | 1083-7159 |
Publisher: | Oxford University Press |
Date Published: | 2005-11-01 |
Start Page: | 792 |
End Page: | 798 |
Language: | English |
DOI: | 10.1634/theoncologist.10-10-792 |
PUBMED: | 16314289 |
PROVIDER: | scopus |
DOI/URL: | |
Notes: | --- - "Cited By (since 1996): 16" - "Export Date: 24 October 2012" - "CODEN: OCOLF" - "Source: Scopus" |